

Healthy Ideas Healthy Returns



HIHR-12 & EIT Health Investor event Programme

Co-organised by HIHR & EIT Health
May 31, 2023


A Room with a Zoo, Antwerp, Belgium

Sponsored by



Science Park
University of Antwerp

Healthy Ideas^{HIHR}
Healthy Returns



Participating Public Research Organisations (PROs)

Supporting PROs



Regular PROs



Preferred partner



Silver partners



HIHR supporters

V-Bio Ventures | NLC Health | Thuja | General Inception | imec.istart.nl

Content

- Content 3
 - HIHR and EIT Health **pitch programme** - May 31, 2023..... 4
 - HIHR pitch sessions – **Start up pitches**..... 5
- EIT Health pitch sessions - **Scale up pitches** 6
- Schedule HIHR **Quickfire sessions**, May 22 - 25, 2023 7
- Sponsors and supporters 8
 - Preferred partner 8
 - Silver sponsors 8
 - Supporters of HIHR..... 9
 - Event sponsor 10
- Expert Session – *The Future of... AI for health*..... 11
- Contact..... 12

HIHR and EIT Health pitch programme - May 31, 2023

Programme

09.00 *Welcome coffee*

10.00 **Healthy Ideas, Healthy Returns** 12th edition

Opening by the moderator - **Jeff Skinner**, Teaching Fellow, London Business School

Welcome - **Clemens Ostrowicz**, Chair HIHR / Team Leader Innovation and Partnering, University of Luxembourg - LCSB

J&J Innovation recap – **Tessy Korthout**, R&D Innovation scout - The Janssen Pharmaceutical Companies of Johnson & Johnson

HIHR Pitch & Q&A session I (projects listed at page 5)

Expert session on *The Future of IT and Health* - **Pieter Meysman**, sr researcher U Antwerp

11.40 *Coffee break*

12.00 HIHR Pitch & Q&A session II

13.05 *Lunch*

14.15 **EIT Health Investor Lounge**

Short Intro - **Menno Kok**, Managing Director EIT Health Belgium & the Netherlands

Invest Health success stories - **Magda Krakowiak**, Director of Business Creation EIT Health & **Allegra Mulas**, Venture Portfolio Manager InvestHealth

EIT Health Pitch & Q&A session I (projects listed at page 6)

15.10 *Break*

15.30 EIT Health Pitch & Q&A session II

Creating value for everybody in the room – discussion with panel and audience lead by **Jeff Skinner**

16.30 *Networking drinks & bites*

Healthy Ideas^{HIHR}
Healthy Returns



HIHR pitch sessions – Start up pitches

HIHR Pitch & Q&A session I

APEX Vision, Perfect sight, shaped to you

Bert van den Bogerd, CEO - MedTech & Diagnostics, U Antwerp

TriGenLys, Phage Lysins - a novel class of enzyme-based antibiotics

Yves Briers, co-founder - Therapeutics & Biotech, U Ghent

Ironix, A Ferroptosis Therapeutics Spin-off

Tom Vanden Berghe, Founder - Therapeutics & Biotech, U Antwerp

SLAM Ortho, Sensor system supporting trauma surgeons that treat patients with fractures

Just Schornagel, co-founder and CEO - MedTech & Diagnostics, YES! Delft

HIHR Pitch & Q&A session II

SparXells™, "Igniting Immunity"

Karim Vermaelen, co-founder, CSO/SMO - Therapeutics & Biotech, U Ghent - alumni pitch, including a 5 minute address on his start-up journey

Ayuvant, Empowering immune immune system for fighting cancer

Lucas Czentner, co-founder/CEO - Therapeutics & Biotech, U Utrecht

Linksight, Create collaborative insights together, without sharing sensitive data!

Martine van de Gaar, CEO - eHealth & Datascience, TNO

SPECIFIX, Patient Specific Fracture Fixation

Matthias Vanhees, co-founder - MedTech & Diagnostics, U Antwerp

Acoustic Insight, Visualize Hearing

Sem Mekking, Commercial Director - MedTech & Diagnostics, Delft Enterprises

Summaries of the Spin off projects available upon registration.

HIHR Pitches will last for a maximum of 7 min presentation, followed by 4 min Q&A (+1 min change).
Due to the density of the programme we must strictly adhere to the schedule. We will close the doors as to not disturb the pitch presentations.

EIT Health pitch sessions - Scale up pitches

EIT Health Pitch & Q&A session I

Brenus Pharma, a discovery platform generating first-in-class tumor-antigen-focused immunotherapies

Léa Perles, Funding, Market Analysis & Partners Manager – Biotechnology, France

CiMaas, immuno-oncology biotech company, pursuing proprietary therapeutics based on Natural Killer (NK) cells

Gerard MJ Bos, CEO – Therapeutics, cell therapy, Maastricht University Medical Center, the Netherlands

EIT Health Pitch & Q&A session II

Azalea Vision, a contact lens-based dynamic light adjusting system, mimicking the normal functionality of the human iris

Enrique Vega, co-founder and CEO – Medtech, imec & University of Ghent, Belgium

SensArs, a patented FDA breakthrough device designated implantable stimulator that treats chronic pain through natural sensations of touch and movement, obtained by stimulation with pin-point precision of nerve fibers

Francesco M Petrini, CEO – Medtech, EPFL, Lausanne

Lys therapeutics, France - **CANCELLED**

Summaries of the companies available upon registration.

EIT Health BeNe Pitches will last for a maximum of 7 min presentation, followed by 4 min Q&A (+1 min change). Due to the density of the programme we must strictly adhere to the schedule. We will close the doors as to not disturb the pitch presentations.

Schedule HIHR Quickfire sessions, May 22 - 25, 2023

HIHR offers new entrepreneurial teams/KTOs venture ideas, not pitch ready yet, the opportunity to test their idea / concept with investors, entrepreneurs and corporates in a 45 minute online session. We highly appreciate your feedback and encourage all investors to participate in these informal sessions to help young entrepreneurial teams with feedback. These sessions for pre-mature projects will take place *online* via MS Teams, according to the following schedule:

Quick fire sessions (subject to change)		
Monday May 22	09.00 – 09.45	Virocell - <i>Cell-based model as an efficacy markers for development of vaccines</i> MedTech & Diagnostics – U Namur
	12.00 – 12.45	CRISParrray - <i>Arrayed CRISPR screening platform for target discovery and validation</i> Therapeutics & Biotech – U Ghent
	17.00 – 17.45	Quantitative analysis of musculoskeletal motion by dynamic computed tomography imaging - <i>AI assisted analysis of CT images of joint motion</i> Therapeutics & Biotech, MedTech & Diagnostics - Vrije Universiteit Brussel
Tuesday May 23	09.00 – 09.45	3DPRISM - <i>Revolutionizing MRI with Personalized RF Coil and Shim Technology: The 3D-PRISM Solution</i> - CANCELLED MedTech & Diagnostics – KU Leuven
	12.00 – 12.45	Indivix - <i>Same day personalised titanium implant delivery</i> MedTech & Diagnostics – KU Leuven
	17.00 – 17.45	PRIBE - <i>Personalizing healthy reference intervals</i> eHealth & Datasience – U Hasselt
Wednesday May 24	09.00 – 09.45	QCQuan - <i>Separating the wheat from the chaff, when it comes to raw data sets</i> eHealth & Datasience – U Hasselt
	12.00 – 12.45	LucidWave - <i>A Novel Handheld Ultrasound Medical Imaging Probe</i> MedTech & Diagnostics – KU Leuven
	17.00 – 17.45	Syntric Medical - <i>Enabling optimal lung cancer treatment</i> MedTech & Diagnostics – TU Eindhoven
Thursday May 25	09.00 – 09.45	Injectable Implants - <i>A new therapy for the prevention and treatment of osteoarthritis</i> Therapeutics & Biotech - Amsterdam UMC

You can mark your interest on the online registration form. Calendar invitations will be sent with the online MS Teams link, to indications 'Highly interested'. Indications 'willing to help' receive an *optional* calendar invite. Summaries of the Quickfire sessions available upon registration.

Sponsors and supporters

Preferred partner



JNJ Innovation

[Johnson & Johnson Innovation](#) seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve people's lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success.

Our mission is to unlock the potential of life science innovation no matter where it originates. We aim to solve the world's toughest health challenges and drive scientific breakthroughs that improve health for everyone, everywhere.

We are comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration:

- Our [Innovation Centers](#) are regional hubs to access the best science and technology in the region. [Make the connection](#) if you are an entrepreneur or an early-stage consumer or medical device company, or a biopharmaceutical company seeking a collaboration to advance a program which is pre-proof of concept in humans.
- Our [JLABS network](#) of incubators support entrepreneurs launching consumer, medical device, or biopharmaceutical companies. [Make the connection](#) if you are seeking incubation space for your early-stage company, or seeking to expand your start-up through an exchange of ideas and collaboration.
- Our [JJDC, Inc.](#) strategic venture arm invests across all sectors and at all stages, from seed-level start-ups to Series B and beyond. [Make the connection](#) if you are seeking a strategic venture partner.
- Our [Janssen Business Development](#) team seeks to identify collaborative opportunities that will create transformative value for our partners and the world. [Make the connection](#) if you are an established pharmaceutical company, or mid-sized to large biotechnology company, and seek a collaboration or merger & acquisition discussion.

Feel free to contact our Benelux External Innovation Partnering leads [Paul Soons](#), [Tessy Korthout](#) or [Peter Roevens](#).

Silver sponsors

INKEF

INKEF Capital is a leading venture capital firm based in Amsterdam with a proven history in backing promising early stage companies in Europe. INKEF takes pride in being a patient, long-term investor with the ability to support companies through several funding rounds all the way up to IPO. From the early stages of being a technology or life science venture, INKEF supports entrepreneurs building their ideas into successful international businesses. Inkef's investments include Onward Medical, Castor, iOnctura, Cardior and GitLAB, Remote among others. For more information please visit: www.inkef.com



Bioqube Ventures

Bioqube Ventures a specialist life sciences investment firm founded in 2016. The team consist out of investment professionals, sector experts and serial entrepreneurs that have a proven track record in successfully building and leading companies on their growth paths.

With a diversified investment strategy, including a venture creation model and industry guidance through selected strategic partnerships, Bioqube Ventures will exclusively invest in the most promising innovative science in Europe. www.bioqubeventures.com



Supporters of HIHR

NLC Health

Pain monitoring systems, ultrasound cancer detection, light therapy for newborns- these are just some of the life-changing technologies that NLC has brought to those in need- that would have otherwise been abandoned. Join us in nurturing healthtech ventures to advance health. www.nlc.health

V-Bio

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the world's premier life science institutes. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors www.v-bio.ventures.

Thuja

Thuja Capital Management (Thuja) manages several venture capital funds aimed at building and scaling companies in the fields of (bio)pharmaceuticals, medtech and digital health. In addition to generating a financial return for its investors, Thuja's investments positively impact the health and well-being of patients. Thuja serves physicians and patients worldwide by providing capital to daring entrepreneurs with ground-breaking product concepts locally. For more information visit www.thujacapital.com.

General Inception

General Inception partners with scientific founders - often first time founders - to ignite their innovation and create transformational companies. We are co-founders bringing together domain expertise, seasoned executive talent, infrastructure resources, and capital to nurture company growth from inception. We started our journey in Palo Alto, California and are now expanding in the Benelux and rest of Europe. www.generalinception.com

Imec.istart.nl

imec.istart.nl, powered by imec and Novel-T, offers tech startups pre-seed funding (between 100.000 and up to 250.000 euro) and tailored support to succeed and grow globally. We have the ambition to support at least 15 high-potential start-ups per year in the Netherlands – often as their first investor. As an investor, we're in it for the long run. www.imecistart.novelt.com

Event sponsor

Science park University of Antwerp

The Science Park University of Antwerp is home to innovative, research-driven companies active in the sectors of Health & Environment.



Centrally located between Antwerp and Brussels alongside a main motorway connection, the park currently consists of about 20.000 m² of labs and office space and offers multiple meeting and conference facilities as well. From co-working to long-term rental or purchase of your own lab and office space, a suitable solution tailored to your needs can be found here. The unique green surroundings are a true bonus.

The Science Park has strong academic connections with knowledge centers and academic institutions in the Antwerp province. Collaborations with research groups of our knowledge partners are actively facilitated.



Science Park residents will also enjoy the benefit of easy access to new talent, as yearly thousands of students and professionals are being trained on campus.

Incubator Darwin supports spin-offs and start-up companies, offering shared infrastructure and business support. The park houses a dynamic community of entrepreneurs for whom training, seminars and networking events are organized on a regular basis.

With unique GMP cell and gene manufacturing capacity on site, the Science Park is especially attractive for companies active in advanced therapy research and development. Other areas of focus include respiratory health care, microbiome, digital health and diagnostics.

We welcome you to visit us in Niel, or at <http://scienceparkuantwerp.be/>.

Interested in becoming a sponsor or supporter as well ? Just send an email to carla@hihr.eu to check out the options.

Expert Session – *The Future of... AI for health*

by Pieter Meysman

Dr. Pieter Meysman is senior researcher at the Department of Computer Science of the University of Antwerp.

With his experience in the application field of machine learning to advance human health he has published more than 70 research articles and patents. He graduated as a PhD in bioscience engineering from the KU Leuven in 2012 and won a number of awards for his research, including most recently the GSK Vaccines award.

Furthermore, his research has directly resulted in two university spin-offs of the University of Antwerp and Antwerp University Hospital. For one of those spin-offs ImmuneWatch, he is CTO. This startup uses AI to decode the human immune system.

During *the future of AI for health* Dr. Pieter Meysman will take us along in the (potential) applications of AI in health, specifically in the immune field. With his insights in the research and the entrepreneurial journal the late and exciting developments will be discussed.

Contact

For additional information and inquiries please contact:

Healthy Ideas ^{HIHR}
Healthy Returns



Claar-els van Delft
Mob +31 6 2848 0549
Claar-els@hihr.eu
www.hihr.eu

Nicolas van de Kerkhof
Mob + 31 6 38164617
nicolas.vandekerkhof@eithealth.eu
<https://eithealth.eu/>